Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

C Axfors, P Janiaud, AM Schmitt, J van't Hooft… - BMC infectious …, 2021 - Springer
Background Convalescent plasma has been widely used to treat COVID-19 and is under
investigation in numerous randomized clinical trials, but results are publicly available only …

Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update

VP Chavda, R Bezbaruah, S Dolia, N Shah… - Process …, 2023 - Elsevier
The pandemic COVID-19 has spread widely throughout the globe and has been responsible
for millions of deaths worldwide. Recently, it has been identified that there is no specific and …

Precision therapeutic targets for COVID-19

ZA Krumm, GM Lloyd, CP Francis, LH Nasif… - Virology journal, 2021 - Springer
Beginning in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
emerged as a novel pathogen that causes coronavirus disease 2019 (COVID-19). SARS …

Contributions of the international plant science community to the fight against human infectious diseases–part 1: epidemic and pandemic diseases

M Lobato Gomez, X Huang, D Alvarez… - Plant biotechnology …, 2021 - Wiley Online Library
Infectious diseases, also known as transmissible or communicable diseases, are caused by
pathogens or parasites that spread in communities by direct contact with infected individuals …

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics

L Chitsike, P Duerksen-Hughes - Virology Journal, 2021 - Springer
The COVID-19 pandemic has put healthcare infrastructures and our social and economic
lives under unprecedented strain. Effective solutions are needed to end the pandemic while …

Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions

EA Tarim, M Anil Inevi, I Ozkan, S Kecili, E Bilgi… - Biomedical …, 2023 - Springer
The COVID-19 pandemic has posed significant challenges to existing healthcare systems
around the world. The urgent need for the development of diagnostic and therapeutic …

Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19

M Takita, T Yoshida, T Tsuchida, Y Nakagama… - Scientific Reports, 2022 - nature.com
Recently, immune response to coronavirus disease (COVID-19) has attracted attention
where an association between higher antibody titer and worsening disease severity has …

Safety and efficacy of convalescent plasma in COVID-19: an overview of systematic reviews

M Franchini, F Corsini, D Focosi, M Cruciani - Diagnostics, 2021 - mdpi.com
Convalescent plasma (CP) from patients recovered from COVID-19 is one of the most
studied anti-viral therapies against SARS-COV-2 infection. The aim of this study is to …

Convalescent plasma therapy against the emerging SARS-CoV-2 variants: delineation of the potentialities and risks

M Dhawan, M Parmar, S Angural… - International Journal of …, 2022 - journals.lww.com
Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) has resulted in a catastrophic pandemic and …

Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis

RA Abeldano Zuniga, SM Coca… - Therapeutic …, 2021 - journals.sagepub.com
The aim was to assess the clinical effectiveness of drugs used in hospitalized patients with
COVID-19 infection. We conducted a systematic review of randomized clinical trials …